Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Seresis
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Administration
- Oral
01
Overview
Seresis is an innovative Swiss formula of natural antioxidants developed by Boehringer Ingelheim. It is marketed as a dietary supplement designed to protect the skin from premature aging by combating harmful free radicals and enhancing the skin's capacity to produce collagen and elastin. It aims to nourish the skin and support its ability to regenerate, helping to maintain its suppleness, health, and natural radiance. Clinical studies have investigated its antioxidant potency in the serum, skin, buccal mucosa cells, and plasma of healthy volunteers.
- Brand names
- Seresis
Beyond the preview
Go deeper on Seresis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seresis.